To assess the safety, tolerability, pharmacokinetics and pharmakodynamics of AZD2820 after multiple ascending doses

Study identifier:D3870C00002

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Phase I, Single Centre, Single-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD2820 after Administration of Multiple Ascending Doses

Medical condition

obesity

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2820, Placebo

Sex

Male

Actual Enrollment

18

Study type

Interventional

Age

18 Years - 45 Years

Date

Study Start Date: 01 Mar 2012
Estimated Primary Completion Date: 01 Dec 2012
Estimated Study Completion Date: 01 Dec 2012

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Basic Science

Verification:

Verified 01 Jan 2014 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria